Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer.

Authors:
Jakob Nikolas Kather
Jakob Nikolas Kather
Institute of Pathology
New Delhi | India
Niels Halama
Niels Halama
University of Heidelberg
Germany

Br J Cancer 2019 Apr 2;120(9):871-882. Epub 2019 Apr 2.

Department of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.

Significant progress in the development of new immunotherapies has led to successful clinical trials for malignant melanoma and non-small cell lung cancer; however, for the majority of solid tumours of the gastrointestinal tract, little or no progress has been seen. The efficacy of immunotherapies is limited by the complexities of a diverse set of immune cells, and interactions between the tumour cells and all other cells in the local microenvironment of solid tumours. A large fraction of immune cells present in and around solid tumours derive from the innate arm of the immune system and using these cells against tumours offers an alternative immunotherapeutic option, especially as current strategies largely harness the adaptive arm of the immune system. This option is currently being investigated and attempts at using the innate immune system for gastrointestinal cancers are showing initial results. Several important factors, including cytokines, chemotherapeutics and the microbiome, influence the plasticity and functionality of innate (myeloid) cells in the microenvironment, and this complexity of regulation has limited translation into successful trials so far. In this review, current concepts of the immunobiology of the innate arm in the tumour microenvironment are presented in the context of clinical translation.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0441-6DOI Listing
April 2019

Publication Analysis

Top Keywords

immune system
16
solid tumours
12
immune cells
8
arm immune
8
innate arm
8
innate immune
8
immune
6
cells
6
option current
4
current strategies
4
immunotherapeutic option
4
tumour cells
4
alternative immunotherapeutic
4
strategies harness
4
harness adaptive
4
investigated attempts
4
attempts innate
4
currently investigated
4
option currently
4
adaptive arm
4

References

(Supplied by CrossRef)
Article in Adv. Immunol.
E Becht et al.
Adv. Immunol. 2016
Article in Curr. Opin. Immunol.
E Becht et al.
Curr. Opin. Immunol. 2016
Article in Cancer Discov.
DG DeNardo et al.
Cancer Discov. 2011
Article in Nat. Rev. Cancer
KE Visser de et al.
Nat. Rev. Cancer 2006
Article in Expert. Opin. Biol. Ther.
D Basile et al.
Expert. Opin. Biol. Ther. 2017
Article in Science
LM Coussens et al.
Science 2013
Article in Nature
A Mantovani et al.
Nature 2008
Article in Nature
SI Grivennikov et al.
Nature 2012
Article in J. Hepatol.
C Brenner et al.
J. Hepatol. 2013
Article in Nat. Rev. Immunol.
L Galluzzi et al.
Nat. Rev. Immunol. 2017
Article in Semin. Cancer Biol.
FR Balkwill et al.
Semin. Cancer Biol. 2012

Similar Publications